B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) on Monday, setting a price target of $63, which is approximately 158.09% above the present share price of $24.41.
Mamtani expects TG Therapeutics to post earnings per share (EPS) of -$0.65 for the fourth quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in TG Therapeutics, with an average price target of $59.
The analysts price targets range from a high of $84 to a low of $26.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $2.03 million and a net profit of -$85.13 million. The company's market cap is $3.49 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.7% and a 40.06% success rate.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.